Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the efficacy and safety of a 5 week double-blind treatment period of VEC-162 as compared to placebo in male and female patients with primary insomnia.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Vanda Pharmaceuticals
NCT06996171 · Primary Insomnia
NCT06850272 · Primary Insomnia
NCT01960452 · Primary Insomnia
NCT00816673 · Primary Insomnia
NCT03314441 · Primary Insomnia
Vanda Investigational Site
Birmingham, Alabama
Vanda Investigational Site
Hot Springs, Arkansas
Vanda Investigational Site
Little Rock, Arkansas
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions